JANG-JAER LEESANG-HENG KOK2021-07-062021-07-0620111043-3074https://www.scopus.com/inward/record.uri?eid=2-s2.0-80051774459&doi=10.1002%2fhed.21511&partnerID=40&md5=747036d4b4ef766fad58d3bdc56066c0https://scholars.lib.ntu.edu.tw/handle/123456789/569695[SDGs]SDG3alendronic acid; pamidronic acid; parathyroid hormone[1-34]; zoledronic acid; bisphophonate induced osteonecrosis of the jaw; bisphosphonate induced osteonecrosis; cancer risk; clinical trial (topic); drug approval; drug induced disease; drug labeling; epiphysis; food and drug administration; human; jaw osteonecrosis; letter; osteoporosis; osteosarcoma; Paget bone disease; priority journalletter10.1002/hed.215112-s2.0-80051774459